WVE - Wave Life Sciences Ltd. Ordinary Shares -  [ ]

Seasonality of Returns By Period

Average daily return by calendar bucket (ClosePriceSA).

Day of Week

Week of Month

Month of Year

Seasonal Path

YTD vs Last Year vs Lookback Avg · closes rebased to 100 at each year's first session
Ticker Details
Wave Life Sciences Ltd. Ordinary Shares
WAVE Life Sciences Ltd is a preclinical therapeutics developer in Singapore. Its pipeline of drugs is intended to cure rare genetic disorders such as Huntington, duchenne muscular dystrophy (DMD) and inflammatory bowel disease.
IPO Date: November 11, 2015
Sector: Healthcare
Industry: Biotech
Market Cap: $697.55M
Activated in VL: True
Average Daily Range
Avg Daily Range: $0.49 | 3.63%
Avg Daily Range (30 D): $0.10 | 2.22%
Avg Daily Range (90 D): $0.14 | 2.56%
Institutional Daily Volume
Avg Daily Volume: .8M
Avg Daily Volume (30 D): 2.8M
Avg Daily Volume (90 D): 2.65M
Trade Size
Avg Trade Size (Sh.): 113
Avg Trade Size (Sh.) (30 D): 147
Avg Trade Size (Sh.) (90 D): 121
Institutional Trades
Total Institutional Trades: 1,757
Avg Institutional Trade: $1.73M
Avg Institutional Trade (30 D): $1.84M
Avg Institutional Trade (90 D): $2.12M
Avg Institutional Trade Volume: .17M
Avg Institutional Trades (Per Day): 1
Market Closing Trades
Avg Closing Trade: $2.27M
Avg Closing Trade (30 D): $2.2M
Avg Closing Trade (90 D): $2.48M
Avg Closing Volume: 253.65K
 
News
May 14, 2026 @ 5:00 PM
Oligonucleotides Clinical Trial Drug Development P...
Source: Delveinsight
Feb 2, 2026 @ 7:16 PM
Wave Life Sciences Reclaims Rare Disease Drug From...
Source: Vandana Singh
Dec 11, 2025 @ 7:01 AM
Golden Cross Alert: 3 Stocks With Major Upside Pot...
Source: Chris Markoch
Dec 10, 2025 @ 2:50 AM
Wave Life Sciences Prices Upsized $350 Million Pub...
Source: Wave Life Sciences
Dec 10, 2025 @ 12:19 AM
Why Wave Life Sciences Stock Crushed it Again Toda...
Source: Eric Volkman
Financials
  TTM Q2 2026 Q1 2026
Basic EPS $-1.08 $-.34 $-.13
Diluted EPS $-1.08 $-.34 $-.13
Revenue $65.37M $2.27M $38.25M
Gross Profit
Net Income / Loss $-202.47M $-69.36M $-26.09M
Operating Income / Loss $-217.92M $-73.8M $-31.3M
Cost of Revenue
Net Cash Flow $159.53M $-176.71M $-57.46M
PE Ratio